For a patient with insomnia characterized by difficulty maintaining sleep, is low‑dose doxepin (3 mg or 6 mg) or trazodone (25–100 mg) the preferred treatment considering efficacy, side‑effect profile, and safety in older adults or those with cardiac conduction disease?

Low-Dose Doxepin is Preferred Over Trazodone for Sleep Maintenance Insomnia

For patients with insomnia characterized by difficulty maintaining sleep, low-dose doxepin (3 mg or 6 mg) is the preferred treatment over trazodone, particularly in older adults and those with cardiac concerns. This recommendation is based on the 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline, which explicitly suggests using doxepin for sleep maintenance insomnia while recommending against trazodone for any type of insomnia 1.

Guideline-Based Recommendations

The AASM guideline provides clear direction:

• Doxepin: WEAK recommendation FOR use in sleep maintenance insomnia (based on 3 mg and 6 mg doses) 1
• Trazodone: WEAK recommendation AGAINST use for either sleep onset or sleep maintenance insomnia (based on 50 mg doses) 1

While both are "weak" recommendations under GRADE methodology (reflecting lower certainty in evidence quality rather than ineffectiveness), the directional guidance is opposite—one favoring use, one opposing it.

Efficacy Profile

Doxepin Advantages

Low-dose doxepin demonstrates sustained efficacy specifically for sleep maintenance parameters:

• Polysomnographic evidence: In a 12-week trial of elderly patients, doxepin 3 mg significantly improved wake time after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), and critically, sleep efficiency in the last quarter of the night and Hour 8—addressing early morning awakenings that plague older adults 2
• Sustained benefit: These improvements persisted through 85 nights without tolerance development 2
• Patient-reported outcomes: Significant improvements in subjective sleep quality, total sleep time, and global outcome measures at all time points (Weeks 1,4, and 12) 2
• Recent meta-analysis: Doxepin 3 mg demonstrated significant superiority over placebo for WASO reduction 3

Trazodone Limitations

Despite widespread off-label use, trazodone lacks robust evidence:

• Insufficient evidence: The AASM guideline found inadequate data to support trazodone's use for insomnia 1
• Systematic review findings: While a 2017 systematic review suggested efficacy for primary and secondary insomnia, it acknowledged methodological limitations and noted most evidence came from studies using higher doses (≥100 mg) in depressed populations 4
• Head-to-head comparison: A 2025 retrospective study found no significant difference between trazodone 100 mg and doxepin 25 mg after trazodone 50 mg failure, with treatment failure rates of 35.2% vs 41.2% respectively (not statistically significant) 5

Safety Considerations

Cardiac Safety: Critical Distinction

For patients with cardiac conduction disease, doxepin has a decisive safety advantage:

• Doxepin cardiac profile: A thorough QT study demonstrated that doxepin up to 50 mg (over 8 times the therapeutic dose) did not prolong QTc intervals, with upper confidence intervals never exceeding 10 milliseconds 6. The FDA label notes cardiovascular effects "including hypotension, hypertension, and tachycardia have been reported occasionally" but does not highlight QT prolongation as a concern 7

• Trazodone cardiac risks: Case reports document trazodone-induced torsades de pointe (TdP), even at standard doses (50 mg daily) in patients without pre-existing QT prolongation risk factors 8. The FDA label for trazodone does not specifically address QT prolongation in detail 9, but published literature demonstrates this risk exists

This cardiac safety distinction is decisive for patients with conduction abnormalities.

Side Effect Profiles

Doxepin (low-dose):

• Minimal next-day residual effects 2
• No reports of memory impairment, complex sleep behaviors, or anticholinergic effects at 3-6 mg doses 2
• No weight gain or increased appetite 2
• Drowsiness most common, but rates comparable to placebo in elderly 2
• FDA label notes anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention) but these are dose-dependent and less prominent at low doses 7

Trazodone:

• Common adverse effects: dizziness, sedation, headache, nausea, somnolence 10
• Priapism risk (rare but serious)
• Orthostatic hypotension, particularly problematic in elderly
• Next-day sedation more common than with low-dose doxepin

Special Population: Older Adults

Doxepin is specifically advantageous in the elderly:

• The 12-week trial demonstrating efficacy was conducted exclusively in elderly subjects (mean age considerations) 2
• Addresses the primary sleep complaints of elderly patients: sleep maintenance and early morning awakenings 2
• Low discontinuation rates and safety profile comparable to placebo in elderly 2
• FDA label notes elderly should start at low doses but supports use with appropriate monitoring 7

Trazodone carries higher risks in elderly:

• Increased fall risk due to orthostatic hypotension
• Greater sensitivity to sedative effects
• The American College of Physicians 2016 guideline found insufficient evidence for trazodone efficacy in chronic insomnia 11

Clinical Algorithm

For sleep maintenance insomnia (difficulty staying asleep, early morning awakening):

1. First-line: Doxepin 3 mg nightly

   • Increase to 6 mg if inadequate response after 1-2 weeks
   • Particularly appropriate for elderly patients
   • Preferred choice if cardiac conduction disease present

2. Avoid trazodone as initial therapy given:

   • Negative guideline recommendation
   • Inferior evidence base
   • Cardiac safety concerns (QT prolongation/TdP risk)
   • Less favorable side effect profile in elderly

3. If doxepin contraindicated (hypersensitivity, glaucoma, urinary retention):

   • Consider suvorexant, eszopiclone, or zolpidem extended-release per AASM guidelines 1
   • Trazodone remains a less-preferred option even in this scenario

Common Pitfalls to Avoid

1. Don't use higher-dose doxepin: The efficacy for insomnia is specific to 3-6 mg doses; higher doses (25-100 mg used for depression) increase anticholinergic burden without additional sleep benefit 7

2. Don't assume trazodone is "safer" because it's commonly used: Off-label popularity does not equal evidence-based superiority; guideline recommendations explicitly oppose its use 1

3. Don't overlook cardiac screening: Always assess for conduction abnormalities before initiating trazodone; consider baseline ECG in at-risk patients given TdP reports 8

4. Don't use trazodone 50 mg as comparator: The AASM recommendation against trazodone was based on 50 mg studies; while higher doses (100-200 mg) are commonly used off-label, this lacks guideline support and increases side effect burden 1, 4

5. Don't forget cognitive-behavioral therapy for insomnia (CBT-I): Both the AASM and American College of Physicians recommend CBT-I as first-line treatment when available; pharmacotherapy is adjunctive 1

Nuanced Considerations

The evidence quality for both medications is limited (hence "weak" GRADE recommendations), but the directional guidance differs fundamentally. The AASM task force reviewed the same evidence base and concluded doxepin merits a positive recommendation while trazodone merits a negative one 1. This distinction, combined with superior cardiac safety data for doxepin 6 versus documented TdP risk with trazodone 8, makes doxepin the evidence-based choice.

A 2026 meta-analysis found that while trazodone may improve subjective sleep perception in depressed patients, agomelatine showed better tolerability profiles 10. However, this addresses depression-related insomnia specifically, not primary insomnia in the general population.

The bottom line: Prioritize low-dose doxepin (3-6 mg) for sleep maintenance insomnia, especially in older adults and those with cardiac concerns. Reserve trazodone only for situations where doxepin is contraindicated and other guideline-supported options have failed.